Charles River Laboratories Stock: Company Reaffirms 2026 Guidance and Sets 2030 Targets
Published on 09/30/2026 at 21:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Charles River Laboratories International, Inc. reaffirmed its 2026 financial guidance at the upper ends of its previous ranges during its Investor Day on September 24, 2026. The company said the outlook reflected continued favorable demand from biopharmaceutical clients. The update was disclosed in a Business Wire release and furnished in a September 24 Form 8-K filed with the U.S. Securities and Exchange Commission.
Pathway to Purpose strategy
The company outlined its Pathway to Purpose strategy, which focuses on modernization, scientific portfolio development and a more customized client approach. Charles River expects its Create the Future program to generate more than $300 million in cumulative savings from 2027 through 2030. It also expects bioanalysis revenue to grow organically at a high-single-digit compound annual growth rate to approximately $450 million in 2030, according to the company release.
Financial targets through 2030
Charles River’s 2026 guidance calls for organic revenue growth at the upper end of a 0% to 1% range and non-GAAP EPS at the upper end of $11.15 to $11.45. The company also set a 2030 non-GAAP operating-margin target of 21.0% to 21.3%. These figures are company guidance or targets rather than reported historical results, and the 2030 targets exclude the impact of future acquisitions and divestitures, the release said.
